<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1705222031
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SALOFALK 500MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MESALAZINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gastro-resistant tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        68.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LOSAN PHARMA GMBH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LOSAN PHARMA GMBH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DR. FALK PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A07EC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets contain the active substance mesalazine, an anti-inflammatory agent used to treat inflammatory bowel disease.</p><p>Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets are used for:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the treatment of acute episodes and prevention of further episodes (recurrence) of an inflammatory disease of the large intestine (colon), known by doctors as ulcerative colitis</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Salofalk</strong><sup>&reg;</sup><strong> 500&nbsp;mg tablets: </strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to mesalazine, to salicylic acid, to salicylates such as acetylsalicylic acid (e.g. Aspirin<sup>&reg;</sup>) or to any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a serious liver or kidney disease.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Before taking Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets you should tell your doctor:<br />&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a history of problems with your lungs, particularly if you suffer from <strong>bronchial asthma. </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a <strong>history of allergy to sulphasalazine, </strong>a substance related to mesalazine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer with problems of your <strong>liver.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer with problems of your <strong>kidney</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after using mesalazine.</p><p>&nbsp;</p><p>Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach in the toilet water. It concerns a chemical reaction between mesalazine and bleach and is harmless.</p><p>&nbsp;</p><p>Further precautions</p><p>During treatment your doctor may want to keep you under close medical supervision, and you may need to have regular blood and urine tests.</p><p>&nbsp;</p><p>In rare cases, in patients who have undergone bowel surgery in the ileocoecal area, it has been observed that Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets are excreted undissolved in the stool. If you notice this occurrence in your own case, please inform your doctor.</p><p>&nbsp;</p><p>Kidney stones may develop with use of mesalazine. Symptoms may include pain in sides of abdomen and blood in urine. Take care to drink sufficient amount of liquid during treatment with mesalazine.</p><p>&nbsp;</p><p>Serious skin reactions including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported in association with mesalazine treatment. Stop using mesalazine and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.</p><p>&nbsp;</p><p><strong>Other medicines and Salofalk</strong><sup>&reg;</sup><strong> 500&nbsp;mg tablets </strong></p><p>Please tell your doctor if you are taking/using any of the medicines mentioned below, as the effects of these medicines may change (interactions):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Azathioprine, 6-mercaptopurine or thioguanine</strong> (medicines used to treat immune disorders)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Certain agents that inhibit blood clotting</strong> (medicines for thrombosis or to thin your blood, e.g.warfarin)</p><p>&nbsp;</p><p>Please tell your doctor or pharmacist if you are taking/using, have recently taken/used or might take/use any other medicines. It may still be all right for you to use Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets and your doctor will be able to decide what is suitable for you.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>You should only use Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets during pregnancy if your doctor tells you to.</p><p>&nbsp;</p><p>You should only use Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets during breast-feeding, if your doctor tells you to, as this medicine may pass into breast milk.</p><p>&nbsp;</p><p>Driving and using machines</p><p>There are no or negligible effects on the ability to drive and use machines.</p><p>&nbsp;</p><p><strong>Salofalk</strong><sup>&reg;</sup><strong> 500&nbsp;mg tablets contain sodium</strong></p><p>This medicinal product contains 49&nbsp;mg sodium (main component of cooking/table salt) in each tablet. This is equivalent to 2.5% of the recommended maximum daily dietary intake of sodium for an adult</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>Method of administration</strong></p><p>Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets are for oral use only.</p><p>Take the tablets in the morning, at midday and in the evening, 1 hour before meals. They should be swallowed whole, not chewed, and taken with plenty of fluid.</p><p><strong>&nbsp;</strong></p><p>Dosage</p><p>&nbsp;</p><p><strong>The recommended dose is:</strong></p><p>&nbsp;</p><p>Adults and the elderly</p><p>&nbsp;</p><p>Unless otherwise prescribed by your doctor, the normal daily doses of mesalazine (the active substance of Salofalk<sup>&reg;</sup>) or Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets, are:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Ulcerative colitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute episode</p></td><td style="vertical-align:top"><p>Prevention of recurrence/</p><p>long-term treatment</p></td></tr><tr><td style="vertical-align:top"><p>Mesalazine (active substance)</p></td><td style="vertical-align:top"><p>1.5 g to 3.0 g</p></td><td style="vertical-align:top"><p>1.5 g</p></td></tr><tr><td style="vertical-align:top"><p>Salofalk<sup>&reg;</sup> 500mg tablets</p></td><td style="vertical-align:top"><p>One tablet three times a day or two tablets three times a day.</p></td><td style="vertical-align:top"><p>One tablet three times a day.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Use in children</strong></p><p>&nbsp;</p><p>There is only limited documentation for an effect in children (age 6-18 years).</p><p><u>&nbsp;</u></p><p><strong>Children 6 years of age and older</strong></p><p>&nbsp;</p><p>Please ask your doctor about the precise dosage of Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets for your child. The dosage depends on how severe the condition is and on your child&rsquo;s body weight.</p><p><strong>&nbsp;</strong></p><p><strong>In acute episodes</strong>: To be determined individually, starting with 30-50 mg per kg body weight per day that should be given in divided doses. The maximum dose is 75 mg mesalazine per kg body weight per day. The total dose should not exceed the maximum adult dose.</p><p><strong>&nbsp;</strong></p><p><strong>To prevent a relapse (ulcerative colitis):</strong> To be determined individually, starting with 15-30 mg per kg body weight per day that should be given in divided doses. The total dose should not exceed the recommended adult dose.</p><p>&nbsp;</p><p>It is generally recommended that half the adult dose should be given to children up to a body weight of 40 kg; and the normal adult dose to those above 40 kg.</p><p>&nbsp;</p><p><strong>Duration of treatment</strong></p><p>The treatment of acute episodes of ulcerative colitis usually lasts 8 weeks. Your doctor will decide how long you are to continue the medication. How long you will use the medicine depends upon the type, severity and course of your condition.</p><p>&nbsp;</p><p>You should follow the treatment with Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets regularly and consistently both during the acute episode of inflammation and also as long-term treatment, because this is the only way the desired therapeutic effect can be achieved.</p><p>&nbsp;</p><p>If you think that the effect of Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets is too strong or too weak, talk to your doctor.</p><p>&nbsp;</p><p><strong>If you take more Salofalk</strong><sup>&reg;</sup><strong> 500&nbsp;mg tablets than you should</strong></p><p><strong>&nbsp;</strong></p><p>Contact a doctor if you are in doubt, so he or she can decide what to do.</p><p>If you use too much Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets on one occasion, just take your next dose as prescribed. Do not use a smaller amount.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Salofalk</strong><sup>&reg;</sup><strong> 500&nbsp;mg tablets</strong></p><p><strong>&nbsp;</strong></p><p>Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Salofalk</strong><sup>&reg;</sup><strong> 500&nbsp;mg tablets</strong></p><p><strong>&nbsp;</strong></p><p>Do not stop taking this product until you have talked to your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>If you get any of the following symptoms after taking this medicine, you should contact your doctor and stop the intake of Salofalk<sup>&reg;</sup> 500 mg tablets immediately:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>General allergic reactions</strong> such as skin rash, fever, joint pain and/or breathing difficulties or a general inflammation of your large bowel (causing severe diarrhoea and abdominal pain). These reactions are very rare.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A marked reduction of your general health, especially if accompanied by fever, and/or a sore throat and mouth. These symptoms can, very rarely, be due to a fall in the number of white cells in your blood, which may make you more prone to developing a serious infection (<strong>agranulocytosis</strong>). Other cells of the blood may also be affected (e.g. platelets or red cells causing <strong>aplastic anaemia</strong> <strong>or thrombocytopenia</strong>) and cause symptoms which may include unexplained bleeding, purple spots or patches under your skin, anaemia (feeling tired, weak and looking pale, especially on lips and nails). A blood test can confirm whether your symptoms are due to an effect of this medicine on your blood. These reactions are very rare.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serious skin rashes</strong> with reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes, widespread rash, fever and enlarged lymph nodes. These can be preceded by fever and flu-like symptoms. These reactions occur in an unknown number of patients (frequency not known).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath, chest pain or irregular heartbeat, or swollen limbs which may be indicative of <strong>cardiac hypersensitivity reactions</strong>. These reactions are rare.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Problems with your kidney function</strong> (can occur very rarely), e.g. a change in the colour or amount of urine produced and swollen limbs or a sudden flank pain (caused by a kidney stone) (occur in an unknown number of patients (frequency not known)).</p><p>&nbsp;</p><p>The following side effects have also been reported by patients using medicines containing mesalazine:</p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, itching</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain, diarrhoea, dyspepsia, wind (flatulence), nausea and vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe abdominal pain because of acute inflammation of the pancreas</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in liver function parameters, changes in pancreatic enzymes</p><p>&nbsp;</p><p><strong>Rare side effects </strong>(may affect less than 1 in 1,000 patients)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice or abdominal pain because of liver and bile flow disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased sensitivity of your skin to sun and ultraviolet light (photosensitivity)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling weak or tired</p><p>&nbsp;</p><p><strong>Very rare</strong><strong> side effects </strong>(may affect less than 1 in 10,000 patients)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness and tingling in the hands and feet (peripheral neuropathy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath, cough, wheezing, lung shadow on x-ray due to allergic and/or inflammatory lung conditions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss and the development of baldness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reversible decrease in semen production</p><p><s>&nbsp;</s></p><p><s>&nbsp;</s></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister and the carton. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&nbsp;&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Salofalk</strong><sup>&reg;</sup><strong> 500&nbsp;mg tablets contain</strong></p><p><strong>&nbsp;</strong></p><p>The active substance in Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets<sup> </sup>is<sup> </sup>mesalazine, and one tablet of Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets contains 500 mg mesalazine.</p><p>&nbsp;</p><p>The other ingredients are:</p><p>basic butylated methacrylate copolymer (Ph.Eur.) ((rel. molar mass: approx. 150000)) (= Eudragit E); calcium stearate (Ph.Eur.) [herbal]; croscarmellose sodium; hydrated iron (III) oxide (E 172); glycine; silica, colloidal anhydrous; hypromellose; Macrogol 6000; methacrylic acid-methyl methacrylate copolymer (1:1) (Ph.Eur.) ((rel. molar mass: approx. 135000)) (= Eudragit L); microcrystalline cellulose; sodium carbonate; povidone K25; talc; titanium dioxide (E171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Salofalk® 500 mg tablets are oval, light yellow to ochre, gastro-resistant tablets, matt with smooth surface; they are not scored. 
Salofalk® 500 mg tablets are available in blister packs of 50 gastro-resistant tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>DR. FALK PHARMA GmbH</p><p>Leinenweberstr. 5</p><p>79108 Freiburg</p><p>Germany</p><p>Tel.: +49 (0) 761 / 1514-0</p><p>Fax: +49 (0) 761 / 1514-321</p><p>Email: zentrale@drfalkpharma.de</p><p>&nbsp;</p><p>For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:</p><p>&nbsp;</p><p>Cigalah Group</p><p>Office 511, 5th floor, Aqaria Building 2,</p><p>Olaya St, Riyadh 11533, Saudi Arabia.</p><p>P.O. Box 50622</p><p>Tel.: +966 11 4191471</p><p>Fax: +966 11 4191652</p><p>Email: info.reg@cigalah.com.sa</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA call center 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Council of Arab Health Ministers</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>This </em></strong><strong><em>is a Medicament</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>The doctor and the pharmacist are the experts in medicines, their benefits and risks.</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Do not by yourself interrupt the period of treatment prescribed for you.</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Do not repeat the same prescription without consulting your doctor.</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Keep all medicaments out of reach of children.</em></p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">Council of Arab Health Ministers</p><p dir="RTL">Union of Arab Pharmacists</p><p dir="RTL">&nbsp;</p><p><strong>This patient information leaflet is approved by the Saudi Food and Drug Authority</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in December 2023.  
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تحتوي أقراص سالوفالك 500 مجم على المادة الفعالة ميسالازين وهي مادة مضادة للالتهاب تستخدم في أمراض الأمعاء الالتهابية.</p><p>&nbsp;</p><p>تستخدم أقراص سالوفالك 500 مجم من أجل:</p><p>- علاج التهاب القولون التقرحي (مرض التهاب الأمعاء الغليظة المزمن) سواء لعلاج النوبة الحادة وكذلك لتجنب الانتكاس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p><strong>لا يسمح بتناول أقراص سالوفالك 500 مجم: &nbsp;</strong></p><p>&nbsp;</p><p dir="RTL">- إذا كنت مصابا بالحساسية تجاه ميسالازين، أو حمض الساليسيليك، أو مركبات الساليسيلات مثل حمض الأسيتيل ساليسيليك (على سبيل المثال الأسبرين<sup>&reg;</sup>)، أو تجاه أي من مكونات هذا الدواء الأخرى (المدرجة في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض خطير بالكبد أو الكلى.</p><p>&nbsp;</p><p><strong>تحذيرات واحتياطات</strong></p><p><strong>&nbsp;</strong></p><p><strong>ينبغي عليك التحدث الى طبيبك قبل استخدام أقراص سالوفالك 500 مجم:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني حاليا أو سابقا من مشاكل في الرئتين، وبصفة خاصة إذا كنت تعاني من<strong> الربو الشعبي.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد <strong>أصبت سابقا بحساسية ضد</strong> <strong>السلفاسالازين</strong> وهي مادة ترتبط بالميسالازين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك اضطراب فى وظائف<strong> الكبد</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك اضطراب فى وظائف <strong>الكلى</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت من قبل بطفح جلدي حاد، أو تقشر الجلد، أو ظهور البثور على الجلد، و/أو قُرح في الفم بعد استخدام ميسالازين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب ميسالازين تغير لون البول إلى اللون الأحمر-البني بعد اتصاله مع مادة التبييض هيبوكلوريت الصوديوم في مياه المرحاض. هذا الأمر يتعلق بتفاعل كيميائي بين ميسالازين ومادة التبييض، وهو تفاعل غير ضار.</p><p dir="RTL">&nbsp;</p><p><strong>احتياطات أخرى</strong></p><p>يقوم طبيبك أثناء فترة العلاج بمتابعتك بعناية وبإجراء فحوصات للدم والبول بانتظام.</p><p>&nbsp;</p><p>في حالات نادرة، تم ملاحظة إفراغ أقراص سالوفالك 500 مجم في البراز، دون أن تذوب، لدى المرضى الذين خضعوا لجراحة بالأمعاء في منطقة اللفائفي الأعوري. إذا لاحظت حدوث هذا الأمر لك، يرجى إخبار طبيبك الخاص.</p><p>&nbsp;</p><p>قد تتكون حصوات الكلى أثناء استخدام ميسالازين. وقد تتضمن الأعراض ألم على جانبي البطن، وظهور دم في البول. احرص على تناول كميات كافية من السوائل أثناء العلاج بالميسالازين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن حدوث تفاعلات جلدية خطيرة بما في ذلك تفاعلات دوائية مصحوبة بكثرة الخلايا اليوزينية وأعراض جهازية (DRESS)، متلازمة ستيفنز-جونسون (SJS)، وانحلال البشرة النخري السمي (TEN)، مع تلقي العلاج بميسالازين. توقف عن استخدام ميسالازين واطلب الرعاية الطبية على الفور إذا لاحظت أيًا من الأعراض المرتبطة بالتفاعلات الجلدية الخطيرة، المذكورة في القسم 4.</p><p dir="RTL">&nbsp;</p><p><strong>تناول أقراص سالوفالك 500 مجم مع الأدوية الأخرى</strong></p><p>الرجاء أن تخبر طبيبك إذا كنت تتناول/تستخدم الأدوية الآتية، فقد يتغير تأثير هذه الأدوية (تفاعلات):</p><p>&nbsp;</p><p>- الآ<strong>زاثيوبرين، 6-مركابتوبورين، أو ثيوغوانين </strong>(أدوية لعلاج اضطرابات الجهاز المناعى)</p><p>-<strong>بعض الأدوية التي تمنع تجلط الدم </strong>(أدوية ضد التخثر، أو هي مسيلة للدم مثل الوارفارين)</p><p>&nbsp;</p><p>الرجاء إخبار طبيبك أو الصيدلاني إذا كنت تتناول/تستخدم حاليا أدوية أخرى، أو كنت تناولت/استخدمت مؤخرا أدوية أخرى، أو تنوى تناول/استخدام أدوية أخرى، فقد يكون العلاج بأقراص بسالوفالك 500 مجم مناسبا مع ذلك. طبيبك يعرف ما هو الأصوب بالنسبة لك في هذه الحالة.</p><p>&nbsp;</p><p><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنت حاملا، أو تظنين أنك حاملا، أو تنوي أن تصبحي حاملا، فاستشيري طبيبك أو الصيدلاني قبل استخدام هذا الدواء.</p><p>إذا كنت حاملا ينبغي عليك تناول أقراص سالوفالك 500 مجم فقط تحت استشارة الطبيب.</p><p dir="RTL">إذا كنت مرضعة ينبغي عليك تناول أقراص سالوفالك 500 مجم فقط تحت استشارة الطبيب، فقد تفرز المادة الفعالة في لبن الأم.</p><p>&nbsp;</p><p><strong>القيادة والقدرة على استخدام الآلات</strong></p><p>ليس لأقراص سالوفالك 500 مجم أي تأثير، أو لها تأثير لا يذكر على القيادة أو القدرة على استخدام الآلات.</p><p>&nbsp;</p><p><strong>تحتوي أقراص سالوفالك 500 مجم على الصوديوم</strong></p><p dir="RTL">يحتوي هذا المنتج الدوائي على 49 مجم من الصوديوم (المكون الرئيسي لملح الطهي/الطعام) في كل قرص. وهذا يكافئ 2.5% من الحد الأقصى الموصى به من نسبة الصوديوم الغذائي اليومي التي يتناولها البالغون.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول هذا الدواء دائما كما أشار عليك طبيبك أو الصيدلاني بالضبط. اسأل طبيبك أو الصيدلاني إذا لم تكن متأكدا.</p><p>&nbsp;</p><p><strong>طريقة الاستخدام</strong></p><p>أقراص سالوفالك 500 مجم مخصصة للتناول عن طريق الفم فقط.</p><p>تناول الأقراص كل صباح وظهر ومساء قبل وجبات الطعام بساعة مع الكثير من الماء، دون مضغها في الفم.</p><p>&nbsp;</p><p><strong>الجرعة</strong></p><p><strong>تبلغ الجرعة الموصى بها:</strong></p><p><strong>&nbsp;</strong></p><p><strong>للبالغين وكبار السن</strong></p><p>ما لم يوصى الطبيب بخلاف ذلك، فإن الجرعات اليومية المعتادة من المادة الفعالة لسالوفالك، الميسالازين، أو من أقراص سالوفالك 500 مجم، هي:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>التهاب القولون التقرحي</strong></p></td></tr><tr><td style="vertical-align:top"><p>منع الانتكاس/</p><p>العلاج طويل الأمد</p></td><td style="vertical-align:top"><p>نوبة حادة</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1.5 جم</p></td><td style="vertical-align:top"><p>1.5 جم إلى 3.0 جم</p></td><td style="vertical-align:top"><p>ميسالازين</p><p>(المادة الفعالة)</p></td></tr><tr><td style="vertical-align:top"><p>قرص واحد ثلاث مرات يوميا.</p></td><td style="vertical-align:top"><p>قرص واحد ثلاث مرات يوميا، أو قرصين ثلاث مرات يوميا.</p></td><td style="vertical-align:top"><p>أقراص سالوفالك 500 مجم</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>الاستخدام للأطفال</strong></p><p>هناك بيانات محدودة عن تأثيره بالنسبة للأطفال (6-18 سنة).</p><p>&nbsp;</p><p><strong>الأطفال 6 سنوات والأكبر سنا</strong></p><p>اسأل طبيبك عن الجرعة المحددة بالضبط لطفلك من أقراص سالوفالك 500 مجم.</p><p>تعتمد الجرعة على درجة شدة المرض ووزن جسم طفلك.</p><p>&nbsp;</p><p dir="RTL"><strong>النوبة الحادة:</strong> يجب تحديدها بشكل فردي، وهي تبدأ بجرعة قدرها 30-50 مجم/كيلو جرام من وزن الجسم/اليوم في جرعات مقسمة. الجرعة القصوى: 75 مجم ميسالازين/ كيلوجرام من وزن الجسم/اليوم. ينبغي ألا تتجاوز الجرعة الاجمالية الجرعة القصوى للبالغين.</p><p>&nbsp;</p><p><strong>لمنع الانتكاس (التهاب القولون التقرحي):</strong></p><p>يجب تحديدها بشكل فردي، وهي تبدأ بجرعة قدرها 15-30 مجم/كيلو جرام من وزن الجسم/اليوم في جرعات مقسمة. &nbsp;ينبغي ألا تتجاوز الجرعة الاجمالية الجرعة الموصى بها للبالغين.</p><p>&nbsp;</p><p>يوصى عموما بنصف جرعة البالغين للأطفال الذين يصل وزن جسمهم حتى 40 كيلوجرام، وبجرعة البالغين المعتادة للأطفال الذين يتجاوز وزنهم 40 كيلو جرام.</p><p>&nbsp;</p><p><strong>مدة العلاج</strong></p><p dir="RTL">يستغرق علاج النوبات الحادة لالتهاب القولون التقرحي عادةً 8&nbsp;أسابيع. سيحدد لك طبيبك المدة التي ينبغي عليك استخدام الدواء فيها. تعتمد مدة العلاج على نوع وشدة ومسار المرض.</p><p>&nbsp;</p><p>ينبغي أن يتم العلاج بأقراص سالوفالك 500 مجم سواء أثناء مرحلة الالتهاب الحاد وكذلك أيضا أثناء العلاج طويل الأجل بانتظام وبصورة مستمرة حتى تتحقق نتيجة العلاج المنشودة.</p><p>&nbsp;</p><p>يرجى التحدث مع طبيبك إذا كان لديك انطباع أن تأثير أقراص سالوفالك 500 مجم قوى جدًا أو ضعيف جدًا.</p><p>&nbsp;</p><p><strong>&nbsp;اذا تناولت كمية أكبر مما ينبغي من أقراص سالوفالك 500 مجم</strong></p><p>أخبر طبيبك في حالة الشك حتى يتمكن من اتخاذ قرار بشأن ما يجب عمله.</p><p>&nbsp;</p><p>إذا تناولت الكثير من أقراص سالوفالك 500 مجم في الجرعة الواحدة، تناول في المرة القادمة الجرعة الموصى بها لهذا الوقت ولا تتناول كمية أقل.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>في حالة نسيان تناول أقراص سالوفالك 500 مجم</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p>&nbsp;</p><p><strong>إذا توقفت عن تناول أقراص سالوفالك 500 مجم</strong></p><p><strong>&nbsp;</strong></p><p>لا توقف العلاج بهذا الدواء دون التحدث مع طبيبك مسبقا.</p><p>&nbsp;</p><p>إذا كان لديك تساؤلات عن استخدام هذا الدواء توجه إلى طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية يمكن أن يكون لهذا الدواء اثار جانبية، على الرغم من أنها لا تصيب جميع الأشخاص.</p><p>&nbsp;</p><p dir="RTL">إذا أصبت بأي من الأعراض التالية بعد تناول هذا الدواء، فينبغي عليك التواصل مع طبيبك، وتوقف عن تناول أقراص سالوفالك 500 مجم على الفور:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية عامة مثل الطفح الجلدي، والحُمّى، وألم المفاصل، و/أو صعوبات في التنفس، أو التهابات عامة في الأمعاء الغليظة لديك (وهو ما يسبب حدوث الإسهال الحاد، وألم بالبطن). هذه التفاعلات نادرة جدا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف واضح في حالتك الصحية العامة، خاصة إذا صاحب ذلك حمى و/أو احتقان في الحلق والفم.<strong> </strong>قد تكون هذه الأعراض<strong>،</strong> في حالات نادرة للغاية<strong>،</strong> نتيجة لانخفاض في عدد الخلايا البيضاء الموجودة في دمك<strong>، </strong>وهو ما قد يجعلك أكثر عرضة للإصابة بعدوى خطيرة<strong> </strong>(<strong>ندرة المحببات</strong>). قد تتأثر أيضا خلايا أخرى في الدم (على سبيل المثال الصفائح الدموية، أو خلايا الدم الحمراء وهو ما يؤدي للإصابة <strong>بفقر الدم اللاتنسجي، أو قلة الصفيحات</strong>)<strong>، </strong>وهو ما يسبب أعراضا قد تتضمن نزيف غير معروف السبب، بقع أرجوانية، أو بقع تحت جلدك، أو فقر الدم (الشعور بالتعب والضعف، وظهور الشحوب، خاصة على الشفتين والأظافر). يمكن أن يؤكد إجراء اختبار للدم إذا ما كانت أعراضك بسبب تأثير لهذا الدواء على دمك أم لا. هذه التفاعلات نادرة جدا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أشكال من الطفح الجلدي الشديد مع بقع حمراء غير منتفخة، دائرية أو تشبه الهدف على الجذع، مع ظهور بثور في مركزها غالبًا، أو تقشر الجلد، أو تقرحات في الفم، والحلق، والأنف، والأعضاء التناسلية والعينين، وطفح جلدي منتشر على نطاق واسع، والحمى، وتضخم العقد اللِمفيَّة. يمكن أن يسبق ظهور هذه الأعراض الإصابة بالحمى وأعراض تشبه أعراض الإنفلونزا. هذه التفاعلات تحدث في عدد غير معروف من المرضى (معدل التكرار غير معروف).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس، ألم بالصدر أو عدم انتظام ضربات القلب، أو تورم الأطراف والذي قد يكون إشارة إلى حدوث تفاعلات فرط الحساسية في القلب. هذه التفاعلات نادرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في وظائف الكلى لديك (يمكن أن تحدث في حالات نادرة جدا)، على سبيل المثال تغير في لون البول أو في كميته، وحدوث تورم بالأطراف أو ألم مفاجئ بالخاصرة (بسبب حصوة في الكلى) (يحدث في عدد غير معروف من المرضى (معدل التكرار غير معروف)).</p><p dir="RTL">لوحظت الاثار الجانبية التالية كذلك لدى المرضى الذين يستخدمون أدوية تحتوي على الميسالازين:</p><p>&nbsp;</p><p><strong>آثار جانبية شائعة </strong>(قد تحدث لما يصل إلى 1 من بين كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، الحكة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة</strong> (قد تحدث لما يصل إلى 1 من بين كل 100 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم البطن، الإسهال، عسر الهضم، الغازات (انتفاخ البطن)، الغثيان والقئ</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم حاد بالبطن بسبب الالتهاب الحاد بالبنكرياس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في مؤشرات وظائف الكبد، وتغيرات في إنزيمات البنكرياس</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية نادرة الحدوث </strong>(قد تحدث لأقل من 1 من بين كل 1000 من المرضى):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان أو آلام بالبطن بسبب اضطرابات فى وظائف الكبد وتدفق الصفراء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حساسية جلدك للشمس والأشعة فوق البنفسجية (التحسس الضوئي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف أو التعب</p><p dir="RTL">&nbsp;</p><p><strong>آثار جانبية نادرة الحدوث جدا </strong>(قد تحدث لأقل من 1 من بين كل 10000 مريض):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنميل والوخز في اليدين والقدمين (اعتلال الأعصاب الطرفية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس، السعال، الأزيز أثناء التنفس، تظليل الرئة في صورة الأشعة السينية بسبب الحساسية و/أو التهاب الرئة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر وحدوث الصلع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض قابل للعكس في إنتاج الحيوانات المنوية</p><p>&nbsp;</p><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p>إذا لاحظت أعراض جانبية توجه لطبيبك أو الصيدلاني. ويعتبر هذا أيضا بالنسبة للأعراض الجانبية التي لم يتم ذكرها في هذا النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p>لا يسمح باستخدام هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على شريط البليستر والعبوة الكرتونية. المقصود بتاريخ الصلاحية هو اليوم الأخير من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">يحفظ في درجة حرارة لا تزيد عن 30 ْم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>محتويات أقراص سالوفالك 500 مجم </strong></p><p><strong>&nbsp;</strong></p><p>-المادة الفعالة لسالوفالك 500 مجم هى الميسالازين ويحتوي كل قرص من سالوفالك 500 مجم على 500 مجم ميسالازين.</p><p>- المواد الأخرى: ميتاكربليت-كوبوليمر (بى ها. اى او ار) (الكتلة الجزيئية النسبية: حوالي 150000) (=ايودراجيت اى)، ستيارات الكالسيوم (بى ها. اى او ار.) (عشبي)، كروسكارميلوز الصوديوم، أكسيد الحديد (111)- هيدروكسيد(اى 172)- جليسين، &nbsp;السيليكا الغروانية اللامائية، ، هيبروميلوز، ماكروجول 6000، حمض الميثاكريليك-ميثاكريلات الميثيل-كوبوليمر (1:1) (بى ها. اى او ار.) (الكتلة الجزيئية النسبية: حوالى 135000) (=ايودراجيت ال)، السيليولوز الدقيق المتبلور، كربونات الصوديوم، البوفيدون كا25، تلك، ثانى أكسيد التيتانيوم (اى 171).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف تبدو أقراص سالوفالك 500 مجم ومحتويات العبوة</strong></p><p>أقراص سالوفالك 500 مجم عبارة عن أقراص بيضاوية مغلفّة صفراء الى اللون الأمغر، مقاومة للعصارة المعدية، غير لامعة بسطح مستو، وغير مقسّمة.</p><p>&nbsp;سالوفالك 500 مجم متوفر في عبوات شرائط بليستر بها 50 قرصًا مقاوما للعصارة المعدية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>حامل تصريح التسويق والجهة المصنعة</strong>:</p><p dir="RTL">شركة دكتور فالك فارما المحدودة</p><p>شارع لاينينفيبر 5</p><p>79108 فريبورج</p><p>ألمانيا</p><p>هاتف: 0-1514 /761 (0) 49+</p><p dir="RTL">فاكس: 321-1514 /761 (0) 49+</p><p>&nbsp; zentrale@drfalkpharma.deالبريد الالكتروني:</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>لمعرفة أي معلومات عن هذا المنتج الدوائي، يرجى التواصل مع الوكيل المحلي لحامل تصريح التسويق:</strong></p><p><strong>&nbsp;</strong></p><p><strong>مؤسسات سقالة</strong></p><p><strong>مكتب 511، الدور الخامس، مبنى العقارية الثانية،</strong></p><p><strong>شارع العليا العام، الرياض 11533، المملكة العربية السعودية.</strong></p><p><strong>صندوق بريد 50622</strong></p><p dir="RTL"><strong>هاتف: 4191471 11 966+</strong></p><p dir="RTL"><strong>فاكس: 4191652 11 966+</strong></p><p dir="RTL"><strong>البريد الالكتروني: </strong>info.reg@cigalah.com.sa</p><p><strong>&nbsp;&nbsp; </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن الأعراض الجانبية:</p><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية (NPC)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد للهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p dir="RTL"><strong>هذا المنتج عبارة عن دواء</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء مستحضر يؤثر على صحتك، واستهلاكه خلافًا للتعليمات يعرضك للخطر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع وصفة الطبيب بدقة، وكذلك طريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي باع لك الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن الطبيب والصيدلي هما الخبيران في الدواء وبنفعه وضرره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ جميع الأدوية بعيدًا عن متناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">اتحاد الصيادلة العرب</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بيانات النشرة الداخلية معتمدة من قبل الهيئة العامة للغذاء والدواء</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاريخ آخر مراجعة لهذه النشرة: ديسمبر 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Salofalk® 500 mg gastro-resistant tablets

Mesalazine
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each gastro-resistant tablet contains 500 mg mesalazine.

Excipients with known effect: sodium carbonate and croscarmellose sodium

For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gastro-resistant tablets

Appearance: oval, light yellow to ochre, gastro-resistant tablets, matt with smooth surface; not scored.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For the treatment of acute episodes and the maintenance of remission of ulcerative colitis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p><u>Adults and elderly</u></p><p>Depending upon the clinical requirements in individual cases, the following daily doses are recommended:</p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Ulcerative colitis</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute episode</p></td><td style="vertical-align:top"><p>Prevention of recurrence/</p><p>long-term treatment</p></td></tr><tr><td style="vertical-align:top"><p>Mesalazine (active substance)</p></td><td style="vertical-align:top"><p>1.5 g - 3.0 g</p></td><td style="vertical-align:top"><p>1.5 g</p></td></tr><tr><td style="vertical-align:top"><p>Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets</p></td><td style="vertical-align:top"><p>3 x 1</p><p>to</p><p>3 x 2</p></td><td style="vertical-align:top"><p>3 x 1</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Paediatric population:</u></p><p>There is only limited documentation for an effect in children (age 6-18 years).</p><p>&nbsp;</p><p><u>Children 6 years of age and older</u></p><p><strong>Active disease: </strong>To be determined individually, starting with 30-50 mg/kg/day in divided doses. Maximum dose: 75 mg/kg/day. The total dose should not exceed the maximum adult dose.</p><p><strong>Maintenance treatment</strong>: To be determined individually, starting with 15-30 mg/kg/day in divided doses. The total dose should not exceed the recommended adult dose.</p><p>It is generally recommended that half the adult dose may be given to children up to a body weight of 40 kg; and the normal adult dose to those above 40 kg.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets should be taken in the morning, at midday and in the evening, 1 hour before meals. They should be swallowed whole, not chewed, and taken with plenty of fluid.</p><p>&nbsp;</p><p>Treatment with Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets should be administered regularly and consistently, both in the acute inflammatory stage and during maintenance therapy in order to achieve the desired therapeutic effect.</p><p>&nbsp;</p><p>The treatment of acute episodes of ulcerative colitis usually lasts 8 weeks. The duration of use is determined by the physician.</p><p>&nbsp;</p><p>For maintenance of remission in ulcerative colitis, the dose can usually be reduced to 1.5 g mesalazine/day (adults and adolescents with a body weight over 40 kg) and 0.75 g mesalazine/day (children/adolescents).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Salofalk® 500 mg tablets are contraindicated in patients with:

	hypersensitivity to the active substance, salicylates or any of the excipients listed in section 6.1
	severe impairment of hepatic or renal function.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blood tests (differential blood count; liver function parameters such as ALT or AST; serum creatinine) and urinary status (dip sticks) should be determined prior to and during treatment, at the discretion of the treating physician. As a guideline, follow-up tests are recommended 14 days after commencement of treatment, then a further two to three tests at intervals of 4&nbsp;weeks.</p><p>&nbsp;</p><p>If the findings are normal, follow-up tests should be carried out every 3 months. If additional symptoms occur, these tests should be performed immediately.</p><p>&nbsp;</p><p>Caution is recommended in patients with impaired hepatic function.</p><p>&nbsp;</p><p>Mesalazine should not be used in patients with impaired renal function. Mesalazine-induced renal toxicity should be considered, if renal function deteriorates during treatment. If this is the case, Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets should be discontinued immediately.</p><p>&nbsp;</p><p>Cases of nephrolithiasis have been reported with the use of mesalazine including stones with a 100% mesalazine content. It is recommended to ensure adequate fluid intake during treatment.</p><p>&nbsp;</p><p>Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach (e.g., in toilets cleaned with sodium hypochlorite contained in certain bleaches).</p><p>&nbsp;</p><p>Serious blood dyscrasias have been reported very rarely with mesalazine. Hematological investigations should be performed if patients suffer from unexplained haemorrhages, bruises, purpura, anaemia, fever or pharyngolaryngeal pain. Salofalk<sup>&reg;</sup> 500 mg tablets should be discontinued in case of suspected or confirmed blood dyscrasia.</p><p>&nbsp;</p><p>Cardiac hypersensitivity reactions (myocarditis, and pericarditis) induced by mesalazine have been rarely reported. Salofalk<sup>&reg;</sup> 500 mg tablets should then be discontinued immediately.</p><p>&nbsp;</p><p>Patients with pulmonary disease, in particular asthma, should be very carefully monitored during a course of treatment with mesalazine.</p><p>&nbsp;</p><p><u>Severe cutaneous adverse reactions</u></p><p>Severe cutaneous adverse reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment. Mesalazine should be discontinued, at the first appearance of signs and symptoms of severe skin reactions, such as skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p>&nbsp;</p><p>Patients with a history of adverse drug reactions to preparations containing sulphasalazine should be kept under close medical surveillance on commencement of a course of treatment with mesalazine. Should Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets cause acute intolerance reactions such as abdominal cramps, acute abdominal pain, fever, severe headache and rash, therapy should be discontinued immediately.</p><p>&nbsp;</p><p>In rare cases, in patients who have undergone bowel resection/bowel surgery in the ileocoecal region with removal of the ileocoecal valve, it has been observed that Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets were excreted undissolved in the stool, due to an excessively rapid intestinal passage.</p><p>&nbsp;</p><p>This medicinal product contains 49 mg sodium per tablet, equivalent to 2.5% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Specific interaction studies have not been performed.</p><p>&nbsp;</p><p>In patients who are concomitantly treated with azathioprine, 6-mercaptopurine or thioguanine, a possible increase in the myelosuppressive effects of azathioprine, 6-mercaptopurine or thioguanine should be taken into account.</p><p>&nbsp;</p><p>There is weak evidence that mesalazine might decrease the anticoagulant effect of warfarin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>There are no adequate data on the use of mesalazine in pregnant women. However, data on a limited number of exposed pregnancies indicate no adverse effect of mesalazine on pregnancy or on the health of the foetus/newborn child. To date no other relevant epidemiologic data are available. In one single case after long-term use of a high dose mesalazine (2-4 g, orally) during pregnancy, renal failure in a neonate was reported.</p><p>&nbsp;</p><p>Animal studies on oral mesalazine do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/ foetal development, parturition or postnatal development.</p><p>&nbsp;</p><p>Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets should only be used during pregnancy if the potential benefit outweighs the possible risk.</p><p>&nbsp;</p><p>Breastfeeding</p><p>N-acetyl-5-aminosalicylic acid and to a lesser degree mesalazine are excreted in breast milk. Only limited experience during lactation in women is available to date. Hypersensitivity reactions such as diarrhoea in the infant cannot be excluded. Therefore, Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets should only be used during breast-feeding if the potential benefit outweighs the possible risk. If the infant develops diarrhoea, the breast-feeding should be discontinued.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No or negligible effects on the ability to drive and use machines have been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>The following undesirable effects have been observed after administration of mesalazine:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:582px"><tbody><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td colspan="5" style="vertical-align:top"><p>Frequency according to MedDRA convention&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p><p>(&ge;&nbsp;1/100 to&nbsp;&lt;1/10)</p></td><td style="vertical-align:top"><p>Uncommon</p><p>(&ge;&nbsp;1/1,000 to&nbsp;&lt;1/100)</p></td><td style="vertical-align:top"><p>Rare</p><p>(&ge;&nbsp;1/10,000 to&nbsp;&lt;1/1,000)</p></td><td style="vertical-align:top"><p>Very rare</p><p>(&lt; 1/10,000)</p></td><td style="vertical-align:top"><p>Not known</p><p>(cannot be estimated from the available data)</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Altered blood counts (aplastic anaemia, agranulocytosis, pancytopenia, neutropenia, leukopenia, thrombocytopenia)</p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions such as allergic exanthema, drug fever, lupus erythematosus syndrome, pancolitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Peripheral neuropathy</p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocarditis, pericarditis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic and fibrotic lung reactions (including dyspnoea, cough, bronchospasm, alveolitis, pulmonary eosinophilia, lung infiltration, pneumonitis)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal pain, diarrhoea, dyspepsia, flatulence, nausea, vomiting, acute pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cholestatic hepatitis&nbsp;</p></td><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash, pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Photosensi-tivity</p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Impairment of renal function including acute and chronic interstitial nephritis and renal insufficiency</p></td><td style="vertical-align:top"><p>Nephrolithia-sis*</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oligospermia (reversible)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthenia, fatigue</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Changes in liver function parameters (increase in transaminases and parameters of cholestasis), changes in pancreatic enzymes (lipase and amylase increased), eosinophil count increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>* See section&nbsp;4.4 for further information.</p><p><u>&nbsp;</u></p><p>Severe cutaneous adverse reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Photosensitivity </u></p><p>More severe reactions are reported in patients with pre-existing skin conditions such as atopic dermatitis and atopic eczema.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are rare data on overdosage (e.g. intended suicide with high oral doses of mesalazine), which do not indicate renal or hepatic toxicity. There is no specific antidote and treatment is symptomatic and supportive.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Intestinal antiinflammatory agents; aminosalicylic acid and similar agents</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ATC code: A07EC02</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Mechanism of action</u></p><p>The mechanism of the anti-inflammatory action is unknown. The results of in-vitro studies indicate that inhibition of lipoxygenase may play a role.</p><p>Effects on prostaglandin concentrations in the intestinal mucosa have also been demonstrated. Mesalazine (5-Aminosalicylic acid / 5-ASA) may also function as a radical scavenger of reactive oxygen compounds.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Mesalazine, orally administered, acts predominantly locally at the gut mucosa and in the submucous tissue from the luminal side of the intestine. It is important, therefore, that mesalazine is available at the regions of inflammation. Systemic bioavailability / plasma concentrations of mesalazine therefore are of no relevance for therapeutic efficacy, but rather a factor for safety. In order to fulfil these criteria, Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets are coated with Eudragit L; they are thus gastro-resistant and release of mesalazine is pH-dependent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General considerations of mesalazine:</u></p><p>&nbsp;</p><p><em>Absorption:</em></p><p>Mesalazine absorption is highest in proximal gut regions and lowest in distal gut areas.</p><p>&nbsp;</p><p><em>Biotransformation:</em></p><p>Mesalazine is metabolised both pre-systemically by the intestinal mucosa and the liver to the pharmacologically inactive N-acetyl-5-aminosalicylic acid (N-Ac-5-ASA). The acetylation seems to be independent of the acetylator phenotype of the patient. Some acetylation also occurs through the action of colonic bacteria. Protein binding of mesalazine and N-Ac-5-ASA is 43% and 78%, respectively.</p><p>&nbsp;</p><p><em>Elimination:</em></p><p>Mesalazine and its metabolite N-Ac-5-ASA are eliminated via the faeces (major part), renally (varies between 20 and 50%, dependent on kind of application, pharmaceutical preparation and route of mesalazine release, respectively), and biliary (minor part). Renal excretion predominantly occurs as N-Ac-5-ASA.</p><p>About 1% of total orally administered mesalazine dose is excreted into the breast milk mainly as N-Ac-5-ASA.</p><p>&nbsp;</p><p><u>Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets specific:</u></p><p>&nbsp;</p><p><em>Distribution:</em></p><p>A combined pharmacoscintigraphic/pharmacokinetic study showed that Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets reach the ileocoecal region after approximately 3-4 hours in fasting subjects and reach the ascending colon within approximately 4&ndash;5 hours. The total transit time in the colon is approximately 17 hours.</p><p>&nbsp;</p><p><em>Absorption:</em></p><p>Release of mesalazine from Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets, begins after a lag-phase of approximately 3&ndash;4 hours.&nbsp; Peak plasma concentrations are reached after approximately 5&nbsp;hours (ileocoecal region) and, at 3 x 500 mg mesalazine/ day under steady-state conditions, are 3.0 &plusmn; 1.6 &micro;g/ml for mesalazine and 3.4 &plusmn; 1.6 &micro;g/ml for the metabolite, N-Ac-5-ASA.</p><p>&nbsp;</p><p><em>Elimination:</em></p><p>The total renal elimination rate for mesalazine and N-Ac-5-ASA over 24 hours during multiple intake (3 x 1 Salofalk<sup>&reg;</sup> 500mg tablets, for 2 days; 1 tablet on the third day=examination day) was approximately 60%. The non-metabolised mesalazine fraction after oral administration was approximately 10%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity, carcinogenicity (rat) or toxicity to reproduction.</p><p>&nbsp;</p><p>Kidney toxicity (renal papillary necrosis and epithelial damage in the proximal tubule (pars convoluta) or the whole nephron) has been seen in repeat-dose toxicity studies with high oral doses of mesalazine. The clinical relevance of this finding is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>List of excipients<u> </u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>Basic butylated methylacrylate copolymer (Ph.Eur.) ((rel. molar mass: approx. 150000)) (= Eudragit E)</p><p>Calcium stearate (Ph.Eur.) [herbal]</p><p>Croscarmellose sodium</p><p>Hydrated iron(III) oxide (E 172)</p><p>Glycine</p><p>Silica, colloidal anhydrous</p><p>Hypromellose</p><p>Macrogol 6000</p><p>Methacrylic acid-methyl methacrylate copolymer (1:1) (Ph.Eur.) ((rel. molar mass: approx. 135000)) (= Eudragit L)</p><p>Cellulose, microcrystalline</p><p>Sodium carbonate, anhydrous</p><p>Povidone K25</p><p>Talc</p><p>Titanium dioxide (E 171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Container:</p><p>Blister: PVC/PE/PVDC (orange-transparent) /aluminium blister foil</p><p>&nbsp;</p><p>Package sizes:</p><p>Blister packs with 50 Salofalk<sup>&reg;</sup> 500&nbsp;mg tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dr. Falk Pharma GmbH
Leinenweberstr. 5
79108 Freiburg
Germany
Tel.: +49 (0)761 1514-0
Fax: +49 (0)761 1514-321
E-mail: zentrale@drfalkpharma.de

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>